NVROのチャート
NVROの企業情報
| symbol | NVRO |
|---|---|
| 会社名 | Nevro Corp （NEVRO CORP） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | ネブロ（Nevro Corp）は医療機器の提供者である。同社は慢性疼痛患者の生活の質を改善する製品を提供することに重点を置く。同社は慢性疼痛の治療のための神経調節プラットフォームであるSenza脊髄電気刺激（SCS）システムを開発・商品化する。同社のHF10療法は慢性疼痛の治療のための神経調節溶液を送達するように設計される。HF10療法は患者が異常感覚を伴わずに持続的鎮痛軽減を達成することを可能にし、不快なショッキングまたは激しい感覚を避けることができる。HF10療法は解剖学的リードの配置に依存する。Senzaシステムは2ヘルツ（Hz）から10000 Hzまでの電気インパルスを生成する。 ネブロは、米国の医療機器メ―カ―。慢性疼痛の治療のための神経調節プラットフォ―ムを開発し、商品化。同社の製品「SENZA」システムは、HF10治療を提供する脊髄刺激(SCS)システムである。SENZAは、10kHzの波形刺激を出すHF10治療に加え、2Hzから10kHzの電気刺激が出るように設計。感覚異常を起こさずに痛みを軽減する。 Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp. |
| 本社所在地 | 1800 Bridge Parkway Redwood City CA 94065 USA |
| 代表者氏名 | D.Keith Grossman |
| 代表者役職名 | President Chief Executive Officer Director |
| 電話番号 | +1 650-251-0005 |
| 設立年月日 | 38777 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 804人 |
| url | www.nevro.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） -37.85600 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 1949.35500 |
| 売上高 | （百万ドル） 387.28900 |
| 企業価値(EV) | （百万ドル） 1837.20200 |
| 当期純利益 | （百万ドル） -49.20500 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Nevro Corp revenues increased 19% to $387.3M. Net loss increased 34% to $49.2M. Revenues reflect United States segment increase of 22% to $321.8M. Higher net loss reflects Selling/General/Admin. Expense - Balanci increase of 19% to $238.5M (expense) Research and Development Expense - Bal increase of 29% to $42.6M (expense). |
NVROのテクニカル分析
NVROのニュース
Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year 2023/01/31 21:05:00 PR Newswire
Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies REDWOOD CITY, Calif., Jan. 31, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of…
Nevro Corp PT Lowered to $37 at Piper Sandler 2023/01/26 11:43:17 Investing.com
https://www.investing.com/news/pro/nevro-corp-pt-lowered-to-37-at-piper-sandler-432SI-2988659
Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results 2023/01/19 12:00:00 PR Newswire
Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic…
Can you still get a good price for Nevro Corp. (NVRO) Shares at this point? 2023/01/13 12:00:00 US Post News
A share of Nevro Corp. (NYSE:NVRO) closed at $36.40 per share on Thursday, up from $35.73 day before. While Nevro Corp. has overperformed by 1.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -60.05%, with highs and lows ranging from $93.69 to $34.70, […]
Nevro Corp PT Lowered to $37 at Wells Fargo 2023/01/11 12:23:12 Investing.com
https://www.investing.com/news/pro/nevro-corp-pt-lowered-to-37-at-wells-fargo-432SI-2978093
Nevro Corp PT Lowered to $75 at JMP Securities 2022/08/05 07:34:07 Investing.com
https://www.investing.com/news/pro/nevro-corp-pt-receives-investment-bank-analyst-rating-update-432SI-2864534
Nevro Corp PT Lowered to $86 at Wells Fargo 2022/08/04 10:36:07 Investing.com
https://www.investing.com/news/pro/nevro-corp-pt-lowered-to-86-at-wells-fargo-432SI-2863221
Recap: Nevro Q2 Earnings 2022/08/03 20:57:40 Benzinga
Nevro (NYSE: NVRO ) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 13.41%, reporting an EPS of $-0.71 versus an … Full story available on Benzinga.com
Nevro Q2 results mixed, co cuts FY 2022 revenue guidance, sees wider FY adj. EBITDA loss 2022/08/03 20:30:20 Seeking Alpha
Nevro press release (NVRO): Q2 GAAP EPS of -$0.71 beats by $0.09.Revenue of $104.21M (+1.8% Y/Y) misses by $0.26M.Sees FY 2022 revenue of $400 million to $410…
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance 2022/08/03 20:05:00 PR Newswire Media
REDWOOD CITY, Calif., Aug. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of…
Nevro Q2 2022 Earnings Preview (NYSE:NVRO) 2022/08/02 21:35:28 Seeking Alpha
Nevro (NVRO) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close.The consensus EPS Estimate is -$0.79 and the consensus Revenue Estimate is…
Boston Scientific to pay Nevro $85 mln to end pain treatment patent fight 2022/08/02 19:03:10 Reuters
Medical-device maker Boston Scientific Corp has agreed to pay Nevro Corp $85 million to settle their patent dispute over spinal-stimulation technology, despite winning $20 million from Nevro at trial last year, the companies said.
Boston Scientific to pay $85M to Nevro as part of settlement to resolve patent litigation 2022/08/01 11:54:08 Seeking Alpha
Boston Scientific (BSX) and Nevro (NVRO) said they reached a settlement in their intellectual property litigations.Under the agreement, Boston Scientific will pay net $85M and…
Nevro And Boston Scientific Reach $85 Mln Settlement Of Ongoing Intellectual Property Litigations 2022/08/01 11:40:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - Medical device makers Nevro Corp. (NVRO) and Boston Scientific Corp. (BSX) announced Monday that they have reached a settlement in all their ongoing intellectual property li…
Fresh Data-Based Insight On Nevro Corp. (NVRO) 2022/07/23 11:00:00 Stocks Register
Nevro Corp. (NYSE:NVRO) concluded the trading at $44.17 on Friday, July 22 with a rise of 1.05% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $43.71 and 5Y monthly beta was reading 1.03 with its price kept floating in the range … Fresh Data-Based Insight On Nevro Corp. (NVRO) Read More »